16 / 16
Page 37
Notes:
allied
academies
Journal of Gastroenterology and Digestive Diseases | Volume 3
May 25-26, 2018 | New York, USA
World Liver Conference 2018
Background:
Assessment of fibrosis in chronic hepatitis has
always been considered of utmost relevance for patient
care in clinical hepatology. Over the last decade, several
non-invasive methods were proposed for diagnosis of liver
fibrosis, including the elastometric measurement of hepatic
stiffness, group of clinical and biochemical parameters, and
combinations of both methods. It has been suggested that
elastography and serum markers are useful techniques for
diagnosing severe fibrosis and cirrhosis and for excluding
significant fibrosis in hepatitis C virus patients. In addition,
hepatic stiffness may also help to prognosticate treatment
response to antiviral therapy.
Aim:
To evaluate changes of Transient elastography values
as well as serum fibronectin and AST to platelet ratio index
in patients (APRI) treated with sofosbuvir- based treatment
regimen.
Methods:
This is a follow-up study including 100 chronic HCV
Egyptian patients treated with Sofosbuvir-based treatment
regimen. Transient elastography values were recorded
as well as serum fibronectin and APRI were calculated at
baseline and SVR12.
Results:
There was a significant improvement of platelets
counts, ALT and AST levels, which in turn cause significant
improvement in APRI scores at SVR12. Liver stiffness
measurements were significantly lower at SVR12 (15.40±8.96
vs 8.82±4.74 kPa, P =0.000). There was significant decline in
serum fibronectin from baseline to SVR 12 (524.14±237.61
vs 287.48±137.67, P=0.000).
Key words:
Hepatitis C Virus (HCV), Liver stiffness (LS),
Transient Elastography (TE) and Fibronectin (FN).
e:
alimena1@yahoo.comLiver stiffness predicts relapse after direct acting antiviral therapy against chronic hepatitis C virus
infection
Ali A Ghweil
1
, Mohamad M Helal
1
, Mohammad Elsenbesy
1
and
Ashraf Khodeary
2
1
South Valley University, Egypt
3
Sohag University, Egypt